Beam Therapeutics (BEAM) Revenue & Revenue Breakdown
Beam Therapeutics Revenue Highlights
Latest Revenue (Y)
$377.71M
Latest Revenue (Q)
$14.27M
Beam Therapeutics Revenue by Period
Beam Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $377.71M | 520.01% |
2022-12-31 | $60.92M | 17.51% |
2021-12-31 | $51.84M | 215916.67% |
2020-12-31 | $24.00K | 33.33% |
2019-12-31 | $18.00K | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
Beam Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $14.27M | 21.21% |
2024-06-30 | $11.77M | 58.87% |
2024-03-31 | $7.41M | -97.66% |
2023-12-31 | $316.19M | 1739.07% |
2023-09-30 | $17.19M | -14.53% |
2023-06-30 | $20.12M | -16.90% |
2023-03-31 | $24.21M | 20.82% |
2022-12-31 | $20.04M | 26.82% |
2022-09-30 | $15.80M | -5.12% |
2022-06-30 | $16.65M | 97.49% |
2022-03-31 | $8.43M | -83.49% |
2021-12-31 | $51.07M | 6593.18% |
2021-09-30 | $763.00K | 12616.67% |
2021-06-30 | $6.00K | - |
2021-03-31 | $6.00K | - |
2020-12-31 | $6.00K | - |
2020-09-30 | $6.00K | - |
2020-06-30 | $6.00K | - |
2020-03-31 | $6.00K | - |
2019-12-31 | $6.00K | - |
2019-09-30 | $6.00K | - |
2019-06-30 | $6.00K | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Beam Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
VRTX | Vertex Pharmaceuticals | $9.84B | $2.77B |
BEAM | Beam Therapeutics | $377.71M | $14.27M |
CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
DNA | Ginkgo Bioworks | $251.46M | $89.05M |
FATE | Fate Therapeutics | $63.53M | $6.77M |
NTLA | Intellia Therapeutics | $36.27M | $9.11M |
CRBU | Caribou Biosciences | $34.48M | $3.46M |
VERV | Verve Therapeutics | $11.76M | $6.87M |
EDIT | Editas Medicine | - | - |
PRME | Prime Medicine | - | $39.31M |
SANA | Sana Bio | - | - |